Showing results (1-10 of 74) with videos related to
Sort By:
Pageof 8
Journal of the Pediatric Infectious Diseases Society|September 7, 2022
The Elusive Role of Airway Infection in Cystic Fibrosis ExacerbationLindsay J Caverly, Donald R VanDevanterAdvanced Drug Delivery Reviews|December 3, 2014
Clinical applications of pulmonary delivery of antibioticsPatrick A Flume, Donald R VanDevanterClinical Investigation|July 7, 2015
Outcome measures for clinical trials assessing treatment of cystic fibrosis lung diseaseDonald R VanDevanter, Michael W KonstanJournal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 2, 2013
Evidence of diminished FEV1 and FVC in 6-year-olds followed in the European Cystic Fibrosis Patient Registry, 2007-2009Donald R VanDevanter, David J PastaCurrent Opinion in Pulmonary Medicine|July 15, 2017
Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapiesDonald R VanDevanter, Nicole Mayer-HamblettMedical Devices (Auckland, N.Z.)|August 24, 2012
Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a reviewDonald R Vandevanter, David E GellerPediatric Pulmonology|April 15, 2005
How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?Donald R VanDevanter, Jill M Van DalfsenJournal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 13, 2017
Feasibility of placebo-controlled trial designs for new CFTR modulator evaluationDonald R VanDevanter, Nicole Mayer-Hamblett, Michael BoyleRespiratory Medicine|January 3, 2012
Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosisDonald R VanDevanter, Manfred Ballmann, Patrick A FlumeJournal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 16, 2014
Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classesElliott C Dasenbrook, Michael W Konstan, Donald R VanDevanterPageof 8